Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

Davids, MS; Roberts, AW; Kenkre, VP; Wierda, WG; Kumar, A; Kipps, TJ; Boyer, M; Salem, AH; Pesko, JC; Arzt, JA; Mantas, M; Kim, SY; Seymour, JF

Author(s): Davids, MS; Roberts, AW; Kenkre, VP; Wierda, WG; Kumar, A; Kipps, TJ; Boyer, M; Salem, AH; Pesko, JC; Arzt, JA; Mantas, M; Kim, SY; Seymour, JF;
Details: Publication Year 2021-09-01,Volume 27,Issue #17,Page 4690-4695
Journal Title: Clinical Cancer Research
Publication Type: Research article
Abstract: PURPOSE: We previously reported a 44% overall response rate (ORR) with the oral BCL-2 inhibitor venetoclax in a phase I study of relapsed/refractory non-Hodgkin lymphoma (NHL). Complete response (CR) was observed in patients with mantle cell lymphoma [(MCL), 21%, n = 6/28] and follicular lymphoma [(FL), 17%, n = 5/29], and partial response (PR) noted in several patients with Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL). Here, we report the long-term outcomes of these four cohorts. PATIENTS AND METHODS: All patients (n = 106) received venetoclax monotherapy in dose cohorts of 200 to 1,200 mg daily until disease progression or unacceptable toxicity. ORR, progression-free survival (PFS), duration of response (DoR), and adverse events (AEs) were evaluated. RESULTS: At a median follow-up of 38.5 months (range, 30.0-46.5), the median PFS for all 106 patients was 5.4 [95% confidence interval (CI), 3.5-8.4] months (FL, 10.8; MCL, 11.3; MZL, 21.2; and WM, 30.4). The median DoR was 14.9 (95% CI, 9.7-27.6) months (FL, 26.6; MCL, 15.7; MZL, 20.1; and WM, 25.3). Achievement of CR versus PR predicted longer DoR in both MCL (31.5 vs. 10.1 months) and FL (37.6 vs. 9.7 months). All grade hematologic AEs were infrequent: neutropenia (19%), anemia (19%), and thrombocytopenia (17%), with no new cytopenias after 2 years on therapy. Nonhematologic AEs included nausea (49%), diarrhea (46%), fatigue (44%), with decreased incidence after 1 year. CONCLUSIONS: Venetoclax monotherapy has a manageable safety profile and achieves durable responses in a subset of patients with FL, MCL, WM, and MZL, particularly in those who achieve CR. Further research is warranted on combination strategies to enhance the durability of response to venetoclax.
Keywords: Antineoplastic Agents/*therapeutic use; Bridged Bicyclo Compounds, Heterocyclic/*therapeutic use; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone/*drug therapy; Lymphoma, Follicular/*drug therapy; Lymphoma, Mantle-Cell/*drug therapy; Recurrence; Sulfonamides/*therapeutic use; Time Factors; Waldenstrom Macroglobulinemia/*drug therapy
Department(s): Haematology
PubMed ID: 34083230
Publisher's Version: https://doi.org/10.1158/1078-0432.CCR-20-4842
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2026-01-28 12:31:57

Last Modified: 2026-01-28 12:33:28